PCSA | Jotup

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Retrieved on:

Lunedì, Maggio 6, 2024

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City.

Key Points:

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City.
Management will be holding one-on-one meetings with investors.

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

Retrieved on:

Giovedì, Aprile 11, 2024

FDA, Project, NGC, Safety, Food, Abstract, PCSA, Plasma, Publication, Incidence, Patient, Doctor of Pharmacy, Database, Capecitabine, AACR, AUC, ODR, Breast cancer, Pharmaceutical industry

HANOVER, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, presented two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2024, including new Phase 1b data on its Next Generation Capecitabine (NGC-Cap) product. These abstracts are available in the Publications section of Processa’s website.

Key Points:

The NGC-Cap Phase 1b trial evaluated ascending doses of capecitabine when combined with a fixed dose of PCS6422 in patients with advanced, relapsed, or refractory progressive gastrointestinal cancer.
NGC-Cap demonstrated greater 5-FU (5-fluorouracil) exposure and lower fluoro-beta-alanine (FBAL) exposure with a better or similar side effect profile compared with monotherapy capecitabine.
“The most recent data for the Phase 1b NGC-Cap study presented at AACR highlight NGC-Cap’s ability to distribute more 5-FU to cancer cells with 5-10 times greater systemic exposure than when capecitabine is administered alone.
“This Phase 1b study is ongoing due to continued patient response and we plan to release final trial data once the database is locked.

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Retrieved on:

Giovedì, Marzo 28, 2024

Patient, Conference, Research and development, Hudson Yards, Cancer, PCSA, Safety

HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference.

Key Points:

HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that George Ng, Chief Executive Officer, will present a corporate update at the MedInvest Biotech and Pharma Investor Conference.
David Young, Processa’s President of Research & Development, will participate virtually.
The conference is being held on April 3 – 4, 2024 at Cooley Law, 55 Hudson Yards, New York, NY 10001.

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Retrieved on:

Lunedì, Marzo 25, 2024

Patient, Cancer, Doctor of Pharmacy, PCSA, Safety

HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.

Key Points:

HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that the Company will have two posters at the American Association for Cancer Research Annual Meeting 2024 in San Diego from April 5-10, 2024.
David Young, PharmD, Ph.D., President of Research and Development at Processa, will be available during the allotted times below and, along with Processa CEO George Ng, will be available for 1-on-1 meetings.
The following posters will be presented:

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Retrieved on:

Mercoledì, Febbraio 21, 2024

Marriott Marquis, Safety, Patient, PCSA, BIO, Cancer, Conference

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Chief Executive Officer George Ng will present a corporate update at the 2024 BIO CEO & Investor Conference being held on February 26 – 27, 2024 at the Marriott Marquis in New York City.

Key Points:

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces that Chief Executive Officer George Ng will present a corporate update at the 2024 BIO CEO & Investor Conference being held on February 26 – 27, 2024 at the Marriott Marquis in New York City.

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Retrieved on:

Mercoledì, Febbraio 14, 2024

Safety, The Winter, PCSA, Patient, Indian stock exchange, Cancer, Conference

HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.

Key Points:

HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces that CEO George Ng will present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference being held February 20 – 23, 2024.
Mr. Ng will be available for one-on-one meetings throughout the conference.
Investors can attend the conference and request a meeting with Mr. Ng by registering here: https://www.microcaprodeo.com/

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Retrieved on:

Martedì, Febbraio 6, 2024

Rule, Patient, Safety, Cancer, PCSA

Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and Processa’s Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy (NGC) drugs following an efficient path to approval. The Company’s approach to drug development, based on more than 30 years of drug development experience, uses its proven Regulatory Science Approach, including the determination of the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of these FDA-approved drugs while maintaining the existing mechanisms of killing the cancer cells. The advantages of Processa’s NGCs are expected to include fewer patients experiencing side effects that lead to dose discontinuation, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each year for each drug -- who will benefit from each NGC drug. Currently under development are three next generation chemotherapy oncology treatments: Next Generation Capecitabine (PCS6422 and capecitabine to treat breast, metastatic colorectal, gastrointestinal, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers).

Key Points:

HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Market and that the matter is now closed.
To regain compliance with the Rule, the Company’s ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 2, 2024.

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Retrieved on:

Giovedì, Febbraio 1, 2024

Security (finance), Exercise, Patient, Safety, PCSA, Prospectus, 3rd Floor, Sale, Cancer, Form

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $7.0 million (excluding any proceeds that may be received upon the exercise of the common warrants).

Key Points:

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $7.0 million (excluding any proceeds that may be received upon the exercise of the common warrants).
H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering.
333-276308) relating to the offering was declared effective by the Securities and Exchange Commission (the "SEC") on January 26, 2024.
The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering.

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Retrieved on:

Venerdì, Gennaio 26, 2024

Patient, Prospectus, Cancer, Form, Sale, 3rd Floor, Safety, PCSA, Exercise, Security (finance)

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be $7.0 million (excluding any proceeds that may be received upon the exercise of the common warrants).

Key Points:

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be $7.0 million (excluding any proceeds that may be received upon the exercise of the common warrants).
The offering is expected to close on or about January 30, 2024, subject to the satisfaction of customary closing conditions.
333-276308) relating to the offering was declared effective by the Securities and Exchange Commission (the "SEC") on January 26, 2024.
The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering.

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Retrieved on:

Giovedì, Gennaio 25, 2024

Capecitabine, Patient, Incidence, NGC, Doctor of Pharmacy, Breast cancer, Cancer, HFS, Safety, PCSA, FDA, Aplastic anemia, BID, Metabolism, Physician, Pharmaceutical industry

HANOVER, MD, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (“NGC-Cap”). From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial. The Phase 2 trial will be in advanced or metastatic breast cancer given FDA’s agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.

Key Points:

From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial.
The Phase 2 trial will be in advanced or metastatic breast cancer given FDA’s agreement that the Phase 1b data can be used to support the design of the Phase 2 trial in breast cancer.
The NGC-Cap Phase 1b trial evaluated capecitabine doses from 75 mg once a day (QD) to 225 mg twice a day (BID).
Although the primary objective of the Phase 1b trial in patients with advanced gastrointestinal (GI) cancer was not to evaluate efficacy, the Phase 1b trial was designed to provide some preliminary data on efficacy.